Literature DB >> 18506587

Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition.

N Patrick McCabe1, Maria Madajka, Amit Vasanji, Tatiana V Byzova.   

Abstract

The molecular mechanisms associated with prostate cancer (PCa) progression within bone remain a topic of intense investigation. With the availability of transgenic mouse strains, a model of PCa for use in immune competent/transgenic mice would be highly beneficial. This study was designed to explore the utility of RM1 mouse PCa cells in investigations of tumor:bone interactions. The efficacies of several implantation techniques were examined for reliably producing intra-bone RM1 tumor growth and bone lesion formation in immune competent mice. Longitudinal monitoring of bone remodeling and lesion phenotypes was conducted by microcomputed tomography (muCT) and histological analyses. Our results indicate that direct intrabone injections of RM1 cells are necessary for tumor growth within bone and direct implantation promotes the rapid development of osteolytic bone lesions with periosteal bone deposition post-cortical breach. In vitro, RM1 cells promote the proliferation of osteoblast (MC3T3-E1) and osteoclast (Raw264.7) progenitors in a dose dependent manner. Conditioned culture media from RM1 cells appears to promote earlier expression of genes/proteins associated with osteoblastic differentiation. While clearly stimulating osteoclast function in vivo, RM1 cells had little effect on differentiation and tartate resistant acid phosphatase (TRAP) expression by Raw264.7 cells. These data, coupled with in vivo muCT images, indicate the ability of RM1 cells to induce mixed, yet predominentally osteolytic, responses in bone and illustrate the potential of RM1 cells as a model of investigating prostate tumor:stroma interactions in immune competent/transgenic mice on a C57BL/6 background.

Entities:  

Mesh:

Year:  2008        PMID: 18506587      PMCID: PMC2864487          DOI: 10.1007/s10585-008-9175-1

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  25 in total

1.  Primer3 on the WWW for general users and for biologist programmers.

Authors:  S Rozen; H Skaletsky
Journal:  Methods Mol Biol       Date:  2000

2.  Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines.

Authors:  S J Hall; T C Thompson
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

Review 3.  Tumor-bone cellular interactions in skeletal metastases.

Authors:  J M Chirgwin; K S Mohammad; T A Guise
Journal:  J Musculoskelet Neuronal Interact       Date:  2004-09       Impact factor: 2.041

4.  [Bone metastasis revealing a primary prostate cancer].

Authors:  A El Otmany; S Bouklata; H Hafid; I Chami; A Jalil; S Benjelloun; A Souadka; M Belabbas
Journal:  J Radiol       Date:  2000-09

5.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation.

Authors:  X Wu; J Wu; J Huang; W C Powell; J Zhang; R J Matusik; F O Sangiorgi; R E Maxson; H M Sucov; P Roy-Burman
Journal:  Mech Dev       Date:  2001-03       Impact factor: 1.882

6.  Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.

Authors:  Julieann F Grant; Toshihisa Iwasawa; Haley W Sinn; D Robert Siemens; Thomas S Griffith; Elizabeth B Takacs; Timothy L Ratliff
Journal:  Int J Cancer       Date:  2006-12-01       Impact factor: 7.396

7.  Prostate-derived soluble factors block osteoblast differentiation in culture.

Authors:  J Martínez; S Silva; J F Santibáñez
Journal:  J Cell Biochem       Date:  1996-04       Impact factor: 4.429

8.  Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.

Authors:  S Kasper; P C Sheppard; Y Yan; N Pettigrew; A D Borowsky; G S Prins; J G Dodd; M L Duckworth; R J Matusik
Journal:  Lab Invest       Date:  1998-03       Impact factor: 5.662

9.  Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients.

Authors:  Michael D Henry; Matthew D Silva; Shenghua Wen; Elizabeth Siebert; Edward Solin; Sudeep Chandra; Peter J Worland
Journal:  Prostate       Date:  2005-12-01       Impact factor: 4.104

10.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

View more
  11 in total

1.  Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone.

Authors:  Olga Zolochevska; Jayne Ellis; Sangram Parelkar; Delphine Chan-Seng; Todd Emrick; Jingna Wei; Igor Patrikeev; Massoud Motamedi; Marxa L Figueiredo
Journal:  Hum Gene Ther       Date:  2013-11-06       Impact factor: 5.695

2.  Macrophage cathepsin K promotes prostate tumor progression in bone.

Authors:  M K Herroon; E Rajagurubandara; D L Rudy; A Chalasani; A L Hardaway; I Podgorski
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

3.  Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone.

Authors:  Hernan Roca; Jacqueline D Jones; Marta C Purica; Savannah Weidner; Amy J Koh; Robert Kuo; John E Wilkinson; Yugang Wang; Stephanie Daignault-Newton; Kenneth J Pienta; Todd M Morgan; Evan T Keller; Jacques E Nör; Lonnie D Shea; Laurie K McCauley
Journal:  J Clin Invest       Date:  2017-11-27       Impact factor: 14.808

4.  Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer.

Authors:  N Patrick McCabe; Bethany A Kerr; Maria Madajka; Amit Vasanji; Tatiana V Byzova
Journal:  Neoplasia       Date:  2011-01       Impact factor: 5.715

5.  Models of Prostate Cancer Bone Metastasis.

Authors:  Sun Hee Park; Matthew Robert Eber; Yusuke Shiozawa
Journal:  Methods Mol Biol       Date:  2019

6.  PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.

Authors:  Arti Verma; Sandeep Artham; Abdulrahman Alwhaibi; Mir S Adil; Brian S Cummings; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2020-03-30       Impact factor: 5.858

7.  Platelets govern pre-metastatic tumor communication to bone.

Authors:  B A Kerr; N P McCabe; W Feng; T V Byzova
Journal:  Oncogene       Date:  2013-09-15       Impact factor: 9.867

8.  Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin β₃ affinity modulation.

Authors:  A Goc; J Liu; T V Byzova; P R Somanath
Journal:  Br J Cancer       Date:  2012-07-05       Impact factor: 7.640

9.  Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer.

Authors:  Ende Zhao; Lin Wang; Jinlu Dai; Ilona Kryczek; Shuang Wei; Linda Vatan; Saleh Altuwaijri; Tim Sparwasser; Guobin Wang; Evan T Keller; Weiping Zou
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

10.  Human fucosyltransferase 6 enables prostate cancer metastasis to bone.

Authors:  J Li; A D Guillebon; J-w Hsu; S R Barthel; C J Dimitroff; Y-F Lee; M R King
Journal:  Br J Cancer       Date:  2013-10-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.